Absence of Frailty in an Older Population of HIV Infected Adults: Experience from an Urban HIV Clinic

Marjorie P Golden1* and Laura F Wilson2
1Department of Internal Medicine and Infectious Diseases, Yale University School of Medicine, USA
2SRC-Yale New Haven Hospital, USA

Corresponding author: Marjorie P Golden, Yale University School of Medicine, SRC-Yale New Haven Hospital, 1450 Chapel Street, New Haven, CT 06511, USA; Tel: 203.789.6983; E-mail: marjorie.golden@ynhh.org

Rec Date: Apr 09, 2017, Acc Date: Apr 19, 2017, Pub Date: Apr 22, 2017
Copyright: © 2017 Golden MP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Introduction

In the US, there has been an increase in the number of older adults living with HIV. At the end of 2013, 42% of HIV-infected adults in the US were >50 and 6% were >65. In 1996-1997, a 20-year-old with HIV infection had a life expectancy of 19 years, while in 2011, life expectancy had improved to 53 years [1]. In our clinic which provides care to approximately 660 HIV-infected adults, about 9% of active patients are >65.

Historically, older adults with HIV infection have had poorer treatment outcomes [2]. Prior to availability of effective antiretroviral therapy (ART), older adults had worse outcomes as evidenced by more rapid decline in CD4 lymphocyte count and shorter survival [3]. Interestingly, despite lower rates of immunologic recovery, the French Hospital database found that older patients actually had better virologic responses [4].

Several factors may contribute to worse overall outcomes for older individuals living with HIV. Thymic function deteriorates with age, so that immunologic recovery is less robust than in younger patients [5]. Prevalence of diabetes is high among patients with HIV infection, affecting 10% of the population [6]. Certain antiretroviral agents may have more toxicity in older patients, a population not typically included in clinical trials. Examples of known adverse effects from antiretroviral therapy include nephrotoxicity, adverse impacts on lipids, insulin resistance, bone loss and accelerated cardiovascular disease [7]. Confounding factors may exist which could potentially increase side effects of ART in older patients. These include alcoholism, chronic kidney disease, viral hepatitis, and psychiatric disease [7]. Finally, it has been hypothesized that polypharmacy, more common in older patients may contribute to toxicities.

HIV associated neurocognitive disorder (HAND) was seen commonly in the pre-ART era, affecting up to 30% of patient with AIDS. With well-controlled HIV infection, rates of HAND in older patients are declining, but there is increasing recognition of overlap between Alzheimer's disease and HIV associated dementia. Identifying and treating such patients is important since neurocognitive impairment may be associated with lower retention in care [8].

With an aging cohort of people living with HIV, there is concern that older individuals may be at especially high risk to develop the "frailty phenotype". A study from San Francisco studied frailty in 155 HIV infected patients with an average age of 57 [9]. Falls were common as were incontinence and depression. While this frail, geriatric syndrome is not well defined, common features generally include history of falls, urinary incontinence and delirium, which may include problems with memory and attention [10,11].

Methods

This study was designed to assess outcomes in a population of geriatric patients cared for in an adult HIV clinic located in New Haven, CT. The vast majority of patients receive both primary and specialty infectious disease care at the same site. Demographic data, CD4 count and viral load are updated at each visit and logged into an AccessR Database. Patients are assessed at each visit for recent falls and flagged as "fall risk" in our electronic medical record (EpicR) if appropriate. There is also routine screening for substance use, adherence and mental health issues.

Patients were identified through query of our Access database, then electronic records of geriatric patients were reviewed. We identified 59 active patients over the age of 65. Demographic data is detailed in (Table 1) and common comorbidities are listed in Table 2.

Results

Fifty patients (85%) had complete virologic suppression with viral load <20 copies/ml. Among nongeriatric patients, 80% had virologic suppression. Four geriatric patients with incomplete virologic suppression had only low-level viremia, with HIV viral load between 21 and 50 copies/ml. Only two patients had viral loads >1000 copies/ml (1930 and 20,100). Median CD4 for geriatric patients was 488 (mean 543). Only 3 patients had CD4 counts below 200 cells/mm3. Among the general population, median CD4 was 541 (mean CD4) 644 (not statistically significant, p value 0.4599 by two-tailed t test).

When patients were assessed for frailty phenotype by screening for presence of low BMI (<19), cognitive decline, fall risk and urinary incontinence, none had all 4 of the risk factors present. When the number of risks factors for each patient was tabulated, 24 (40.7%) had no risk factors identified. Eleven patients (18.6%) had 2 frailty conditions present and 20 (33.9%) had only 1 risk identified. Only two patients had any documentation of aspiration, a condition predisposing to pneumonia and often present in elderly patients with dementia (Table 3).

Discussion

Our population of HIV-infected adults over the age of 65 had excellent immunologic and virologic control. Only 4 patients in this cohort (6.8%) had been diagnosed with dementia which is much lower than what was reported in the San Francisco cohort despite the fact that our population was older (median age 69 compared to 57 in their cohort). In addition, none of the patients in our study had all 4 factors that we screened for as markers of frailty.
We found a lower prevalence of cognitive decline than what has been previously reported in the literature. This may reflect improved long term virologic control, but our numbers were small so it is difficult to draw specific conclusions. We were also unable to assess whether a history of substance use in the past was a risk factor for development of cognitive decline. However, we did find that mental health issues and ongoing substance use issues were prevalent, reinforcing the need to focus resources on these problems.

### Table 1: Demographics.

| Category                  | Count |
|---------------------------|-------|
| Gender                    |       |
| Male                      | 40    |
| Female                    | 19    |
| Race                      |       |
| NonHispanic Black         | 31    |
| NonHispanic White         | 23    |
| Hispanic                  | 5     |
| Median Age                | 69 years (range 66-81) |
| 66-69 years               | 35 (59%) |
| 70-74 years               | 19 (32%) |
| 75-79 years               | 4 (7%) |
| >80 years                 | 1 (2%) |
| HIV viral load <20 copies/ml | 50 (85%) |
| CD4<200 cells/mm³         | 3     |

### Table 2: Comorbid conditions.

| Condition                        | Count |
|----------------------------------|-------|
| Hypertension                     | 41 (69.5%) |
| Diabetes mellitus                | 18 (30.5%) |
| Chronic kidney disease           | 21 (35%) |
| Lipid disorder                   | 24 (41%) |
| Coronary artery disease          | 7 (12%) |
| Median BMI                        | 26 (range 16-49) |
| Mean BMI                          | 26.1  |
| Median number non-HIV medications | 10 (range 2-28) |

### Mental health disorder

| Condition                         | Count |
|-----------------------------------|-------|
| Depression                        | 18    |
| Cognitive decline/HIV dementia    | 4     |
| Bipolar disease                   | 3     |
| Schizophrenia                     | 2     |
| Anxiety                           | 5     |
| Active substance use disorder     | 8     |
| Cocaine                           | 4     |
Alcohol

Conditions indicating frailty

| Condition                                      | Number of Patients (% of Total) |
|------------------------------------------------|---------------------------------|
| BMI <19                                         | 5 patients (8.5%)               |
| Patients identified as fall risk                | 15 patients (25.4%)             |
| Patients with urinary incontinence              | 3 patients (5%)                 |
| Patients with cognitive decline                 | 4 (6.8%)                        |
| All 4 frailty conditions present                | 0                               |
| 3 frailty conditions present                    | 4 (6.8%)                        |
| 2 frailty conditions present                    | 11 (18.6%)                      |
| 1 frailty condition present                     | 20 (33.9%)                      |
| No frailty conditions present                   | 24 (40.7%)                      |

Table 3: Frailty indicators.

Conclusion

In summary, our population of older adults with HIV disease had very high levels of function with low prevalence of frailty and excellent immunologic and virologic control. Given the continued gains in life expectancy for people living with HIV, increased attention also needs to be given to managing other comorbidities such as hypertension, chronic kidney disease, dyslipidemia and cardiovascular disease which are likely going to be the important causes of illness for this population. Moving forward, this means a need for more coordination between multidisciplinary geriatrics centers and HIV providers.

References

1. Marcus JL, Chao C, Leyden W, Xu L, Quesenberry CP, et al. (2016) Narrowing the gap in life expectancy for HIV+ compared with HIV-individuals. CROI/ISA-USA, Boston, Massachusetts.
2. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group (2008) Response to combination antiretroviral therapy: variation by age. AIDS 22: 1463–1473.
3. Philips AN, Lee CA, Elford J, Webster A, Janossy G, et al. (1991) More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. J Acquir Immune Defic Syndr 4: 970–975.
4. Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, et al. (2004) Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age: results from the French Hospital Database on HIV. AIDS 18: 2029-2038.
5. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, et al. (1998) Changes in thymic function with age and during the treatment of HIV infection. Nature 396: 690–695.
6. Hernandez-Romieu AC, Garg S, Rosenberg ES, Thompson-Paul AM, Skarbinski J et al. (2017) Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009–2010. BMJ Open Diabetes Res Care 5: 1-000304.
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services.
8. Jacks A, Wainwright DA, Salazar L, Grimes R, York M, et al. (2015) Neurocognitive deficits increase risk of poor retention in care among older adults with newly diagnosed HIV infection. AIDS 29: 1711-1714.
9. Greene M, Covinsky KE, Valcour V, Miao Y, Madamba J, et al. (2015) Geriatric Syndromes in Older HIV-Infected Adults. J Acquir Immune Defic Syndr 69:161-167.
10. Inouye SK, Studentski S, Tinetti ME, Kuchel GA (2007) Geriatric Syndromes: Clinical, Research and Policy Implications of a Core Geriatric Concept. J Am Geriatr Soc 55: 780–791.
11. Nguyen N, Holodny M (2008) HIV Infection in the Elderly. Clin Interv Aging 3: 453–472.